TrialJournal of cancer research and clinical oncology2019

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.

Cai Xiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.